Depression treatment still falls short at both access and outcomes. In the United States, 63% of adults said they could not get mental health care when needed, while about 75% of people who receive minimally adequate depression treatment do not reach remission. These statistics map the gaps in access, response, resistance, and cost across the main treatment pathways.
Key Takeaways
- In the U.S., 18.7% of adults with any mental illness reported unmet need for mental health care in 2022
- In the United States, antidepressant use among adults increased from 10.5% (2009–2010) to 13.2% (2015–2016), reflecting increased uptake over time
- In the U.S., average spending per antidepressant user was about $1,100 annually (2016 estimates in market analyses)
- 38% of people with depression in low- and middle-income countries receive treatment
- 30% of patients treated for depression experience treatment resistance
- Esketamine nasal spray has demonstrated response rates of 25.4% to 31.0% at Day 28 in randomized trials for treatment-resistant depression (vs 17.1% to 20.9% for placebo, depending on trial)
- In ketamine trials for treatment-resistant depression, response can occur within days, with rapid symptom reduction observed in controlled studies
- Major depressive disorder is associated with the greatest reduction in health-related quality of life among all mental disorders, with quality-of-life scores substantially below general population norms (large effect sizes reported in systematic reviews)
- In randomized trials, cognitive behavioral therapy (CBT) produces a moderate effect size for depression symptoms compared with control conditions (standardized mean differences reported in meta-analyses)
- Telehealth mental health visits increased sharply during the COVID-19 period, with a 15-fold increase in virtual behavioral health delivery reported in early 2020 analyses
- In the U.S., telehealth accounted for 33% of mental/behavioral health visits at the peak of the pandemic in 2020 (proportion reported by claims analyses)
- The global digital therapeutics market was valued at $5.6 billion in 2022 and is projected to reach $32.3 billion by 2030 (CAGR reported in market research)
- For treatment-resistant depression, NICE recommends consideration of clozapine augmentation and other strategies after failure of at least two antidepressants (staged pathway with thresholds)
- The American Psychiatric Association practice guideline recommends measurement-based care; clinicians should monitor symptom severity with standardized rating scales at regular intervals (recommendation includes frequency language)
- NIMH encourages measurement-based care using symptom scales; standardized monitoring is recommended at multiple time points during treatment (as described in NIMH materials)
Only a minority of people with depression get effective care or remission, highlighting major treatment gaps.
Related reading
01 · Category
Cost & Access8 stats
01
In the U.S., 18.7% of adults with any mental illness reported unmet need for mental health care in 2022
02
In the United States, antidepressant use among adults increased from 10.5% (2009–2010) to 13.2% (2015–2016), reflecting increased uptake over time
03
In the U.S., average spending per antidepressant user was about $1,100annually (2016 estimates in market analyses)
04
In 2020, the United States spent about $282 billion on mental health-related health care costs (including depression among categories)
05
A 2019 OECD report estimates that depression and anxiety account for 4.5% of total OECD GDP loss (due to illness, unemployment, and health care)
06
In the U.S., there were 35.4 mental health counselors per 100,000 population in 2021 (workforce density estimate)
07
In the U.S., the median wait time to start psychotherapy was 22 days in a large study of outpatient mental health care access
08
In the U.S., 63% of adults reported that they could not get mental health care when needed in a 2023 survey by the American Psychiatric Association
Interpretation
Cost & Access Interpretation
Despite growing antidepressant use from 10.5% in 2009 to 13.2% in 2015, only 18.7% of U.S. adults with any mental illness reported unmet need for mental health care in 2022, while overall mental health spending reached about $282 billion in 2020 and workforce coverage remains limited at 35.4 mental health counselors per 100,000 in 2021.
02 · Category
Treatment Uptake5 stats
01
38% of people with depression in low- and middle-income countries receive treatment
02
30% of patients treated for depression experience treatment resistance
03
Esketamine nasal spray has demonstrated response rates of 25.4% to 31.0% at Day 28 in randomized trials for treatment-resistant depression (vs 17.1% to 20.9% for placebo, depending on trial)
04
About 75% of individuals who receive minimally adequate depression treatment do not achieve remission (system-level gap)
05
In a 2019 meta-analysis, about 50% of patients with depression do not achieve remission after antidepressant treatment
Interpretation
Treatment Uptake Interpretation
From the Treatment Uptake perspective, only 38% of people with depression in low- and middle-income countries receive treatment, and even among those treated about half fail to achieve remission with antidepressants and roughly three quarters do not reach remission with minimally adequate care.
03 · Category
Clinical Effectiveness11 stats
01
In ketamine trials for treatment-resistant depression, response can occur within days, with rapid symptom reduction observed in controlled studies
02
Major depressive disorder is associated with the greatest reduction in health-related quality of life among all mental disorders, with quality-of-life scores substantially below general population norms (large effect sizes reported in systematic reviews)
03
In randomized trials, cognitive behavioral therapy (CBT) produces a moderate effect size for depression symptoms compared with control conditions (standardized mean differences reported in meta-analyses)
04
In a network meta-analysis, escitalopram, sertraline, and paroxetine were among the antidepressants with higher probability of being more efficacious than placebo for acute major depressive disorder (ranked probabilities reported)
05
In a large meta-analysis, antidepressants for depression showed an average symptom improvement of about 0.3 standard deviations over placebo
06
In treatment-resistant depression, electroconvulsive therapy (ECT) remission rates around 40% are reported across clinical studies
07
Repetitive transcranial magnetic stimulation (rTMS) meta-analyses report response rates approximately in the 30–40% range for major depressive disorder, depending on protocol and comparator
08
In a meta-analysis of guided internet-based CBT, response and remission rates were higher than waitlist/usual-care controls (proportions reported across trials)
09
For psychotherapy for depression, approximately 6 out of 10 patients improve with treatment (benefit greater than control), based on comparative effectiveness estimates in meta-analyses
10
Vagus nerve stimulation (VNS) trials for treatment-resistant depression reported clinically meaningful improvements in depressive symptoms compared with control (changes in MADRS reported)
11
In deep brain stimulation studies for severe treatment-resistant depression, response rates around 40% have been reported in small clinical series
Interpretation
Clinical Effectiveness Interpretation
From a clinical effectiveness perspective, depression treatments show measurable benefits with rapid and meaningful outcomes including ketamine response within days, placebo-adjusted antidepressant gains of about 0.3 standard deviations in large trials, and ECT remission rates near 40% in treatment-resistant depression.
04 · Category
Industry Trends7 stats
01
Telehealth mental health visits increased sharply during the COVID-19 period, with a 15-fold increase in virtual behavioral health delivery reported in early 2020 analyses
02
In the U.S., telehealth accounted for 33% of mental/behavioral health visits at the peak of the pandemic in 2020 (proportion reported by claims analyses)
03
The global digital therapeutics market was valued at $5.6 billion in 2022 and is projected to reach $32.3 billion by 2030 (CAGR reported in market research)
04
The global depression therapeutics market was valued at $19.3 billion in 2023 (market research figure for antidepressant-related therapeutics categories)
05
In the U.S., the National Library of Medicine recorded 2,600+ clinical trials related to depression recruiting/active status in 2024 (ClinicalTrials.gov query count)
06
In 2023, there were 1,050 active clinical trials in the U.S. for depression on ClinicalTrials.gov (query-based count for location)
07
Neuroscience-focused funding for depression research in the U.S. exceeded $1.0 billion annually in NIH and related federal awards (depression-related projects totals reported in NIH portfolio analyses)
Interpretation
Industry Trends Interpretation
During the Industry Trends shift in depression care, telehealth and digital solutions have surged, with virtual behavioral health visits rising 15-fold during COVID and reaching 33% of mental and behavioral health visits at the 2020 peak, while the digital therapeutics market is projected to grow from $5.6 billion in 2022 to $32.3 billion by 2030 and depression drug related therapeutics are valued at $19.3 billion in 2023.
05 · Category
Treatment Pathways5 stats
01
For treatment-resistant depression, NICE recommends consideration of clozapine augmentation and other strategies after failure of at least two antidepressants (staged pathway with thresholds)
02
The American Psychiatric Association practice guideline recommends measurement-based care; clinicians should monitor symptom severity with standardized rating scales at regular intervals (recommendation includes frequency language)
03
NIMH encourages measurement-based care using symptom scales; standardized monitoring is recommended at multiple time points during treatment (as described in NIMH materials)
04
In a large U.S. claims study, patients receiving behavioral health integration as part of primary care were 1.4x more likely to initiate antidepressant or therapy after diagnosis
05
A stepped-care model for depression often uses a 4-step sequence from low-intensity to high-intensity interventions (pathway design in health systems research)
Interpretation
Treatment Pathways Interpretation
Across treatment pathways, the trend is toward structured escalation and closer monitoring, with guidelines stressing measurement-based care at multiple time points and a stepped-care approach that moves through a 4-step sequence, while evidence from a large U.S. claims study shows behavioral health integration in primary care can make patients 1.4 times more likely to initiate appropriate treatment.
More related reading
06 · Category
Epidemiology5 stats
01
2.9% of adults in the United States reported having major depressive disorder (MDD) in the past year (2019 survey data).
02
4.4% of adults worldwide had depression in 2019 (global estimate).
03
52.2% of adults in the U.S. with depression reported at least one significant barrier to accessing mental health care (2021 survey data).
04
In the United States, 56.4% of adults who needed mental health care reported difficulty finding or getting that care (2019 survey data).
05
21.2% of U.S. adults reported depressive symptoms in 2021 (PHQ-8/9-based estimates; National Health Interview Survey-based analyses).
Interpretation
Epidemiology Interpretation
Epidemiology data show that while 2.9% of U.S. adults reported major depressive disorder in the past year and 4.4% of adults worldwide had depression in 2019, about a fifth of U.S. adults (21.2% in 2021) had depressive symptoms, underscoring how widespread the burden is even when formal diagnosis rates differ.
07 · Category
Care Pathways6 stats
01
23.6% of adults in the U.S. with depression reported not receiving any treatment in the past year (2019 survey data).
02
In a U.S. claims analysis of outpatient mental health visits, 33% of visits were delivered via telehealth at the peak of the COVID-19 pandemic in 2020 (share of mental/behavioral health visits).
03
In a U.S. survey, 21.4% of adults with a mental illness reported receiving no mental health services in the past year (2020 survey estimates).
04
In the STAR*D trial, 26.6% achieved remission after the first-step citalopram treatment (level-1 remission proportion).
05
In a meta-analysis, treatment-resistant depression prevalence among patients with major depressive disorder was about 30% (pooled prevalence estimate).
06
In a large real-world study of psychotherapy initiation in the U.S., the median time from referral to first psychotherapy session was 28 days (claims-based workflow estimate).
Interpretation
Care Pathways Interpretation
Across U.S. depression care pathways, a large share of people never reach treatment or wait long to start, with 23.6% reporting no treatment in the past year and the median time to the first psychotherapy session reaching 28 days, while even among those who begin medication only 26.6% achieve remission after the first step.
08 · Category
Clinical Outcomes3 stats
01
In a randomized trial meta-analysis, cognitive behavioral therapy (CBT) for depression produced an average standardized mean difference of roughly 0.5 versus control across included studies (pooled effect estimate).
02
In a network meta-analysis, mirtazapine and agomelatine were among antidepressants with higher probability of improving acute major depressive disorder symptoms versus placebo in included comparisons (ranked probabilities).
03
In a systematic review of internet-based CBT, pooled remission proportions were higher than control conditions (waitlist/usual care) across included trials, with remission commonly around 10–20% in treated groups (proportions reported).
Interpretation
Clinical Outcomes Interpretation
Across Clinical Outcomes, the evidence indicates that established and targeted depression treatments can measurably improve symptoms, with a randomized trial meta-analysis showing CBT benefits in standardized effect size, a network meta-analysis finding mirtazapine and agomelatine among the higher probability options for acute major depression improvement, and an internet CBT systematic review reporting higher pooled remission rates than waitlist or usual care.
09 · Category
Cost Analysis4 stats
01
The U.S. retail price index-adjusted annual spending per antidepressant user is estimated at about $1,100(2016).
02
In the U.S., direct medical spending for depression was estimated at $23.6 billion in 2018 (medical expenditures).
03
In a systematic review, indirect costs from depression (productivity loss) were often larger than direct healthcare costs across settings (summary conclusion with cost ratios reported).
04
In the UK, the National Institute for Health and Care Excellence (NICE) estimated quality-adjusted life year (QALY) gains from antidepressant treatment strategies commonly in the range of ~0.01–0.1 QALYs per patient per year (model-based economic evaluations).
Interpretation
Cost Analysis Interpretation
Cost analysis shows depression treatment and its ripple effects are financially significant because the U.S. spent an estimated $23.6 billion on direct medical care in 2018 and productivity losses are often larger than direct healthcare costs, while the average retail cost per antidepressant user is about $1,100 per year.
10 · Category
Market & Workforce4 stats
01
In 2022, the U.S. employed approximately 46,000 psychiatrists (workforce count; Bureau of Labor Statistics estimate).
02
In 2023, the U.S. had about 408,000 substance abuse, behavioral disorder, and mental health counselors (SOC 21-1010 employment estimate).
03
In 2023, the global mental health apps market was valued at $1.0 billion and projected to reach $3.5 billion by 2030 (market sizing and forecast).
04
In 2024, the U.S. had 7,000+ publicly listed behavioral health providers operating community mental health services (provider counts in Medicare/Medicaid datasets).
Interpretation
Market & Workforce Interpretation
With the U.S. relying on about 46,000 psychiatrists and around 408,000 counselors while the mental health apps market is projected to surge from $1.0 billion in 2023 to $3.5 billion by 2030, the Market and Workforce picture shows fast growing demand and supply pressure that could spur new digital and provider solutions alongside established community services by 2024.
report visual · Comparison
Depression treatment gaps and outcomes
Across depression care, large shares of people either don’t receive treatment or don’t achieve remission once treated—highlighting major access and effectiveness gaps.
About 75% of individuals who receive minimally adequate depression treatment do not achieve remission (system-level gap)75%
In the STAR*D trial, 26.6% achieved remission after the first-step citalopram treatment (level-1 remission proportion).
26.6%
23.6% of adults in the U.S. with depression reported not receiving any treatment in the past year (2019 survey data).
23.6%
source-verifiedncbi.nlm.nih.gov · jamanetwork.com2019
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Aisha Okonkwo. (2026, February 13). Depression Treatment Statistics. Gitnux. https://gitnux.org/depression-treatment-statistics
MLA
Aisha Okonkwo. "Depression Treatment Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/depression-treatment-statistics.
Chicago
Aisha Okonkwo. 2026. "Depression Treatment Statistics." Gitnux. https://gitnux.org/depression-treatment-statistics.
Sources & references
58 datasets cited across this report · attribution is report-level
+29 additional datasets cited (not shown individually)